Search:
Tokushima University ⟩ Graduate School of Biomedical Sciences ⟩ 医学域 ⟩ Endwed Collaborative Research ⟩ Contribution ⟩ Department of General Medicine and Community Health Science ⟩ (Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1. Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Thi Na Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara and Yasuhiko Nishioka :
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.,
Thoracic Cancer, Vol.15, No.5, 369-378, 2024.
(Tokushima University Institutional Repository: 119383,   DOI: 10.1111/1759-7714.15200,   PubMed: 38146645)
2. Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka :
FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.,
Respiratory Medicine Case Reports, Vol.45, 101893, 2023.
(Tokushima University Institutional Repository: 119403,   DOI: 10.1016/j.rmcr.2023.101893,   PubMed: 37485237)

Proceeding of Domestic Conference:

1. Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yugo Matumura, Seiya Ichihara, Takeshi Imakura, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Yuko Toyoda, Kayoko Hase, Eiji Takeuchi, Takashi Haku and Yasuhiko Nishioka :
The impacts of G-CSF on the therapeutic efficacy of chemo-immunotherapy for extensive-stage small cell lung cancer.,
2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
2. Hirokazu Ogino, Nguyen Na Thi, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi and Yasuhiko Nishioka :
Fluoropyrimidine has a potential to be an immunologically optimal partner ofimmunotherapy for thoracic malignancies.,
2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
3. Yuki Tsukazaki, Makoto Tobiume, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Masaki Hanibuchi, Hirohisa Ogawa, Hiromitsu Takizawa and Yasuhiko Nishioka :
非小細胞肺癌症例における腫瘍浸潤線維細胞の走化因子と疾患予後との関連性についての解析,
第64回日本肺癌学会学術集会, Nov. 2023.
4. Hirokazu Ogino, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Masaki Hanibuchi, Hiroshi Nokihara and Yasuhiko Nishioka :
フッ化ピリミジンは胸部腫瘍の免疫原性細胞死を誘導し免疫チェックポイント阻害薬の至適併用薬となり得る,
第64回日本肺癌学会学術集会, Nov. 2023.
5. Ryohiko Ozaki, Hiroshi Nokihara, Yuki Tsukazaki, Yohei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
進展型小細胞肺癌において2次治療が受けられない患者の臨床的背景の検討,
第64回日本肺癌学会学術集会, Nov. 2023.
6. Yohei Yabuki, Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, Hiroto Yoneda, Ryohiko Ozaki, Yuki Tsukazaki, Masaki Hanibuchi, Hiroshi Nokihara and Yasuhiko Nishioka :
HIF1A 阻害による腫瘍細胞由来 CXCL10/11 制御を介した抗 PDL1 抗体への耐性克服,
第82回日本癌学会学術総会, Sep. 2023.
7. Yuki Tsukazaki, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohhei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
肺癌における腫瘍浸潤線維細胞の走化因子とその疾患予後に及ぼす影響についての解析,
第27回日本がん分子標的治療学会学術集会, Jun. 2023.